Digital RESI Pitch Session

Interested in Connecting? Please contact:
Glenn Laub

Message the company or request a 1:1 meeting here

TDLI’s product, Pleurafoam™, is being developed to improve the management and outcomes of patients with malignant pleural effusions. TDLI has developed a unique foam formulation, Pleurafoam™, that improves coverage, regardless as to whether the procedure is performed in the operating room or at the bedside. The product has been designed to cover the entire pleural space, which will provide more complete delivery of the active ingredient, talc. The product favors therapeutic bedside pleurodesis over other modalities because it is more effective, less costly, easier to use, and less invasive.

Pitch Video